N/A
Completed N=1,713
Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes
Type2 Diabetes
Source: ClinicalTrials.gov NCT03362112 ↗
Enrolled (actual)
1,713
Serious AEs
—
Results posted
Apr 2022
Primary outcomePrimary: Lipoprotein-associated Phospholipase A2 — 238.4 ng/ml
Summary
Lipoprotein-associated phospholipase A2 (LP-PLA2) is a good marker of cardiovascular risk and inflammation. This study aims at the characteristic and clinical significance of LP-PLA2 test in patients with type 2 diabetes(T2D).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Lipoprotein-associated Phospholipase A2 |
238.4 | — |
| SECONDARY HbA1c |
9.1 | — |
| SECONDARY LDL-c |
2.5 | — |
| SECONDARY Diabetic Complication |
— | — |
| SECONDARY C Peptide |
— | — |
Eligibility Criteria
Inclusion Criteria
- Patients with T2D and the diagnostic criteria of T2D is according to the World Health Organization in 1999.
Exclusion Criteria
- Patients use systemic steroidal anti-inflammatory drugs.
- Patients are pregnant.
- Patients with an acute infection.
Data sourced from ClinicalTrials.gov (NCT03362112). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.